Gilead Sciences
Kelley Paul lost money on the investment in Gilead Sciences, which makes an antiviral drug used to treat COVID-19, a spokesperson said.
Coronavirus patients around the world have been rushing to join remdesivir studies that opened in hospitals in the last few weeks.
Gilead Sciences made $3 billion selling the drug, used to prevent the spread of HIV, last year.
Sales of Biktarvy are expected to be about $1 billion this year.
WHAT'S HAPPENING
The list price will be $373,000.
"The Achilles heel for us is drug resistance because the virus is incredibly quick to mutate."
Documents examined by Kaiser Health News shed light on the workings of the Trump administration's “Drug Pricing and Innovation Working Group."
